Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

PXMD

PaxMedica Inc

Dec 05 • 04:00PM ET

0.7664

Dollar change -0.0769
Percentage change -9.12	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-21.77	Insider Own	0.00%	Shs Outstand	1.01M	Perf Week	-14.84%
Market Cap	0.77M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	1.01M	Perf Month	-70.52%
Income	-17.59M	PEG	-	EPS next Q	-0.88	Inst Own	1.72%	Short Float / Ratio	32.43% / 0.18	Perf Quarter	-88.70%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-	Short Interest	0.33M	Perf Half Y	-96.66%
Book/sh	-0.50	P/B	-	EPS next Y	-	ROA	-381.84%	Target Price	3.00	Perf Year	-98.39%
Cash/sh	1.14	P/C	0.67	EPS next 5Y	-	ROE	-1900.19%	52W Range	0.73 - 69.19	Perf YTD	-97.78%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-98.89%	Beta	0.26
Dividend %	-	Quick Ratio	0.99	Sales past 5Y	0.00%	Gross Margin	-	52W Low	5.71%	ATR	0.62
Employees	5	Current Ratio	0.99	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	34.38	Volatility	15.54% 34.50%
Optionable	No	Debt/Eq	-	EPS Q/Q	68.59%	Profit Margin	-	Rel Volume	0.32	Prev Close	0.84
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	1.84M	Price	0.77
Recom	1.00	SMA20	-55.88%	SMA50	-75.68%	SMA200	-95.34%	Volume	587,225	Change	-9.12%

Dec-01-23 01:30PM	PaxMedica Closes on Public Offering Reaching Estimated $7M (NewMediaWire)
Nov-22-23 04:10PM	PaxMedica Announces Closing of $7.0 Million Public Offering (ACCESSWIRE) +27.50%
10:27AM	Why Is PaxMedica (PXMD) Stock Up 57% Today? (InvestorPlace)
08:30AM	PaxMedica Announces Pricing of $7M Public Offering (NewMediaWire)
Nov-21-23 09:00AM	PaxMedica News of FDA Type-B Meeting Shared in Audio Broadcast (NewMediaWire) -18.37%
03:15PM	Loading…
Nov-20-23 03:15PM	Why Is PaxMedica (PXMD) Stock Down 40% Today? (InvestorPlace) -44.00%
09:15AM	PaxMedica Announces Pricing of $7.0 Million Public Offering (ACCESSWIRE)
Nov-17-23 03:00PM	PaxMedica Releases Q3 2023 Financial Report, Corporate Update (NewMediaWire) -13.37%
08:00AM	PaxMedica Inc. Featured in Syndicated Broadcast Highlighting FDA Type-B Meeting to Review PAX-101 Pivotal Trial Data (GlobeNewswire)
Nov-15-23 06:50PM	PaxMedica, Inc. Announces Third Quarter 2023 Financial Results and Business Update (ACCESSWIRE) +11.52%
08:30AM	PaxMedica Hoping to Boost Patient Independence with Potential ASD Treatment (NewMediaWire)
Nov-10-23 09:00AM	PaxMedica CMO Featured in Latest Bell2Bell Podcast Release (NewMediaWire) -19.67%
Nov-09-23 08:30AM	PaxMedica Phase 2 Study Results Published in Peer-Reviewed Journal (NewMediaWire) -30.92%
08:00AM	PaxMedica's Chief Medical Officer Discusses FDA Meeting Highlights on The Bell2Bell Podcast (GlobeNewswire)
Nov-07-23 11:15AM	Why Is PaxMedica (PXMD) Stock Up 95% Today? (InvestorPlace) +47.54%
08:00AM	Loading…
08:00AM	PaxMedica Announces Publication of Its Autism Spectrum Disorder Phase 2 Study Results in Peer-reviewed Journal (ACCESSWIRE)
Nov-02-23 08:30AM	PaxMedica Engages Bourne Partners to Explore Future Monetization of Potential Priority Review Voucher (PRV) (GlobeNewswire) -17.31%
Oct-31-23 08:00AM	PaxMedica Acquires Suramin Research Assets from Rediscovery Life Sciences to Accelerate NDA Submission for PAX-101 (GlobeNewswire) +11.76%
Oct-30-23 11:30AM	PaxMedica Announces 1-for-17 Reverse Stock Split (GlobeNewswire) -16.68%
Oct-26-23 02:42PM	Why Is PaxMedica (PXMD) Stock Up Today? (InvestorPlace) +26.96%
01:51PM	PaxMedica's Research on Low Dose Suramin for Autism Spectrum Disorder Accepted for Publication (GlobeNewswire)
08:00AM	PaxMedica Holds Important FDA Type-B Meeting to Review PAX-101 Pivotal Trial Data (ACCESSWIRE)
Oct-18-23 10:10AM	The Bell2Bell Podcast featuring Howard Weisman, CEO and Buzz Woods of PaxMedica, Inc. (Nasdaq: PXMD) (GlobeNewswire) +34.62%
Oct-10-23 08:00AM	PaxMedica Announces Gold Sponsorship of The BRAIN Foundation's Synchrony Symposia 2023 (ACCESSWIRE) +7.96%
Aug-30-23 08:00AM	PaxMedica to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) -8.83%
Aug-16-23 08:30AM	PaxMedica Appoints David Hough M.D. as Chief Medical Officer (GlobeNewswire)
Aug-09-23 04:15PM	PaxMedica, Inc. Announces Second Quarter 2023 Financial Results and Business Update (GlobeNewswire)
Aug-08-23 09:00AM	PaxMedica to Join Fireside Chat with PCG Advisory Following Positive Top Line Results from PAX-HAT-301 Study (ACCESSWIRE)
Jul-24-23 08:00AM	PaxMedica Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301 (GlobeNewswire) +7.10%
Jul-06-23 08:00AM	PaxMedica Grants Exclusive Pharmacy Distribution Rights for PAX-101 to Vox Nova, LLC (GlobeNewswire)
08:30AM	Loading…
Jun-22-23 08:30AM	PaxMedica Comments on Common Stock Volatility (GlobeNewswire)
Jun-20-23 08:30AM	PaxMedica CEO Interviewed by The BRAIN Foundation (GlobeNewswire) -14.42%
Jun-14-23 08:00AM	PaxMedica Submits Clinical Trial Request in Autism Spectrum Disorder (GlobeNewswire) -9.60%
Jun-08-23 08:00AM	PaxMedica Enters Research Collaboration Agreement With PoloMar Health for Phase II Study in Autism Spectrum Disorder (GlobeNewswire) +7.63%
Jun-01-23 08:00AM	PaxMedica Completes HAT-301 Registrational Trial for PAX-101 (GlobeNewswire)
May-15-23 04:13PM	PaxMedica, Inc. Provides First Quarter 2023 Business Update; Phase 3 HAT-301 Top Line Results Expected in Second Half 2023 (GlobeNewswire)
Apr-19-23 08:30AM	PaxMedica Announces NASDAQ Closing Bell Ringing to Celebrate Initial Public Offering and Autism Awareness Month (GlobeNewswire) -10.00%
Mar-29-23 07:21PM	PaxMedica, Inc. Provides Business Update and Reports Fourth Quarter 2022 Financial Results (GlobeNewswire) +7.98%
Mar-20-23 08:00AM	PaxMedica Holds Meeting of Scientific Advisory Board (GlobeNewswire)
Feb-27-23 10:22AM	7 Stocks With the Highest Short Interest This Week (InvestorPlace)
Feb-15-23 07:30AM	PaxMedica Releases 2022 Shareholder Letter (GlobeNewswire) +8.64%
Feb-03-23 08:00AM	PaxMedica, Inc. Secures $3.2 Million Growth Capital From Lind Partners (GlobeNewswire) +9.03%
Jan-20-23 01:31PM	PaxMedica to Present at the Jan 26th Virtual Investor Summit Microcap Event (GlobeNewswire) +5.07%
Dec-14-22 08:00AM	PaxMedica, Inc. Launches Updated Corporate Website at PaxMedica.com (GlobeNewswire) -8.73%
Nov-22-22 08:00AM	PaxMedica to Present at the Benchmark Companys Upcoming Discovery One-on-One Investor Conference (GlobeNewswire) -7.80%
Nov-17-22 08:29PM	PaxMedica, Inc. Enters Into Committed Equity Investment Agreement for up to $20 Million With Lincoln Park Capital (GlobeNewswire) -9.64%
Nov-15-22 08:00AM	PaxMedica, Inc. Provides Business Update and Reports Third Quarter 2022 Financial Results (GlobeNewswire) +15.79%
Nov-08-22 08:00AM	PaxMedica Initiates Clinical Program to Advance PAX-101 Towards FDA Submission (GlobeNewswire)
Oct-24-22 08:00AM	PaxMedica Appoints Stefan Schwabe MD, PhD as Chief Medical Officer (GlobeNewswire) -15.35%
Oct-03-22 08:00AM	PaxMedica Appoints Specialty Pharma Industry Leader Charles J. Casamento to Its Board of Directors (GlobeNewswire) -5.83%
Aug-26-22 09:50AM	Craft Capital Management Announces Pricing of Initial Public Offering for PaxMedica, Inc. (ACCESSWIRE)
08:00AM	PaxMedica, Inc. Announces Pricing of Initial Public Offering (GlobeNewswire)
Aug-24-22 03:27PM	Neurodevelopment Biotech PaxMedica To Debut On NASDAQ Tomorrow (Benzinga)

PaxMedica, Inc. is a clinical stage biopharmaceutical company. It engages in the business of developing drug candidates for the treatment of autism spectrum disorder, Fragile X syndrome tremor-ataxia, and Human African Trypanosomiasis. The company was founded by Michael L. Derby on April 5, 2018 and is headquartered in Tarrytown, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rome Zachary	Director	Nov 27	Sale	1.03	359	370	15,959	Nov 29 04:07 PM
Derby Michael	10% Owner	Nov 27	Sale	1.03	185	190	25,650	Nov 29 04:08 PM
Weisman Howard J.	Chairman and CEO	Nov 27	Sale	1.03	162	166	38,047	Nov 29 04:08 PM
LaRochelle Karen	Director	Nov 27	Sale	1.03	35	36	2,907	Nov 29 04:07 PM
Coelho John F	Director	Nov 27	Sale	1.02	12	12	4,642	Nov 29 04:09 PM
Rome Zachary	Director	Oct 27	Sale	0.18	16,301	3,012	277,390	Oct 30 04:13 PM
Derby Michael	10% Owner	Oct 27	Sale	0.19	9,175	1,740	439,171	Oct 30 04:12 PM
Weisman Howard J.	Chairman and CEO	Oct 27	Sale	0.19	8,049	1,524	649,549	Oct 30 04:11 PM
LaRochelle Karen	Director	Oct 27	Sale	0.19	1,679	317	49,994	Oct 30 04:12 PM
Coelho John F	Director	Oct 27	Sale	0.19	570	108	79,090	Oct 30 04:12 PM
Weisman Howard J.	Chairman and CEO	Aug 30	Sale	0.45	22,535	10,053	657,598	Aug 30 04:09 PM
Rome Zachary	Director	Aug 30	Sale	0.47	4,801	2,235	293,691	Aug 30 04:09 PM
Weisman Howard J.	Chairman and CEO	Aug 29	Sale	0.48	9,596	4,650	680,133	Aug 30 04:09 PM
Rome Zachary	Director	Aug 29	Sale	0.48	8,792	4,257	298,492	Aug 30 04:09 PM
Derby Michael	10% Owner	Aug 29	Sale	0.48	6,540	3,169	448,346	Aug 30 04:08 PM
LaRochelle Karen	Director	Aug 29	Sale	0.48	456	221	51,673	Aug 30 04:09 PM
Coelho John F	Director	Aug 29	Sale	0.49	23	11	79,660	Aug 30 04:10 PM
Rome Zachary	Director	Aug 28	Sale	0.49	12,000	5,862	307,284	Aug 30 04:09 PM
Weisman Howard J.	Chairman and CEO	Aug 28	Sale	0.49	12,000	5,858	689,729	Aug 30 04:09 PM
Derby Michael	10% Owner	Aug 28	Sale	0.49	7,000	3,452	454,886	Aug 30 04:08 PM
LaRochelle Karen	Director	Aug 28	Sale	0.50	2,000	1,002	52,129	Aug 30 04:09 PM
Coelho John F	Director	Aug 28	Sale	0.52	774	403	79,683	Aug 30 04:10 PM
Rome Zachary	Director	Aug 22	Sale	0.54	30,000	16,236	319,284	Aug 23 04:12 PM
Rome Zachary	Director	Aug 21	Sale	0.58	20,000	11,626	349,284	Aug 23 04:12 PM
Weisman Howard J.	Chief Executive Officer	Mar 09	Sale	1.44	3,495	5,033	541,633	Mar 09 09:47 PM
Rome Zachary	Chief Operating Officer	Mar 09	Sale	1.44	3,371	4,854	288,452	Mar 09 09:47 PM
Derby Michael	Executive Chairman	Mar 09	Sale	1.43	2,143	3,064	324,430	Mar 09 09:47 PM
LaRochelle Karen	Director	Mar 09	Sale	1.48	335	496	42,415	Mar 09 09:46 PM
Coelho John F	Director	Mar 09	Sale	1.48	130	192	67,235	Mar 09 09:46 PM
Weisman Howard J.	Chief Executive Officer	Mar 08	Sale	1.46	32,397	47,300	545,128	Mar 09 09:47 PM
Rome Zachary	Chief Operating Officer	Mar 08	Sale	1.47	30,034	44,150	291,823	Mar 09 09:47 PM
Weisman Howard J.	Chief Executive Officer	Mar 07	Sale	1.53	23,551	36,033	577,525	Mar 07 07:18 PM
Rome Zachary	Chief Operating Officer	Mar 07	Sale	1.53	23,432	35,851	321,857	Mar 07 07:17 PM
Derby Michael	Executive Chairman	Mar 07	Sale	1.55	15,134	23,458	326,573	Mar 07 07:17 PM
Derby Michael	Executive Chairman	Mar 06	Sale	1.72	13,828	23,784	341,707	Mar 07 07:17 PM
Weisman Howard J.	Chief Executive Officer	Mar 06	Sale	1.72	13,589	23,373	601,076	Mar 07 07:18 PM
Rome Zachary	Chief Operating Officer	Mar 06	Sale	1.72	13,560	23,323	345,289	Mar 07 07:17 PM
Derby Michael	Executive Chairman	Mar 03	Sale	1.90	18,968	36,039	355,535	Mar 03 08:10 PM
Weisman Howard J.	Chief Executive Officer	Mar 03	Sale	1.90	15,323	29,114	614,665	Mar 03 08:11 PM
Rome Zachary	Chief Operating Officer	Mar 03	Sale	1.89	13,199	24,946	358,849	Mar 03 08:11 PM
LaRochelle Karen	Director	Mar 03	Sale	1.90	1,097	2,084	42,750	Mar 03 08:12 PM
Rome Zachary	Chief Operating Officer	Mar 02	Sale	1.94	12,952	25,127	372,048	Mar 03 08:11 PM
Weisman Howard J.	Chief Executive Officer	Mar 02	Sale	1.94	11,679	22,657	629,988	Mar 03 08:11 PM
Derby Michael	Executive Chairman	Mar 02	Sale	1.94	10,497	20,364	374,503	Mar 03 08:10 PM
LaRochelle Karen	Director	Mar 02	Sale	1.94	7,736	15,008	43,847	Mar 03 08:12 PM
Coelho John F	Director	Mar 02	Sale	1.93	3,013	5,815	67,365	Mar 03 08:12 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PXMD

PaxMedica Inc

Upgrade your FINVIZ experience